- Low risk of side effect because using intrinsic protein.
- Modulates functions of only antigen-presenting cells.
- Demonstrated in SLE, Allergy, Rheumatoid Arthritis models.
Background and Technology
HLA-G is secreted in placenta, and protect fetus from maternal immune system. Administration of HLA-G has proven to be effective for autoimmune diseases, and certain kinds of cancer are known to express HLA-G to avoid host immunity.
Among seven splicing variant of HLA-G, HLA-G2 is unique in the fact that it only suppresses monocytes, macrophages and dendritic cells, and does not affect T-cells, NK-cells or B-cells, which means it can remain a part of the immune system.
The researchers have demonstrated the therapeutic effect by recombinant, and PEGylated HLA-G2 in several autoimmune disease models.
- Established recombinant HLA-G2 production by E-coli expression.
- HLA-G2 was successfully Pegylated and improved stability.
- recombinant HLA-G2 (15µg/body) and PBS, were injected ip. twice/week for 12 weeks in SLE model mice.
- Amount of anti-dsDNA antibodies after 72 days and urinary protein value (albumin/ creatinine) after 86 days were much lower in HLA-G2 treatment group (upper fig.).
- H&E, PAM, PAS staining confirmed reduced infiltration of mononuclear cells and vasculitis in the kidney, as well as reduced proliferation of glomerular mesangial cells (lower Fig.).
- PEGylated HLA-G2 increased therapeutic effects.
- The effect was also confirmed by mouse Collagen-Induced Arthritis (CIA) model and atopic dermatitis model.
- Proposed mechanism was confirmed by human cell analysis.
PCT filed (No publications)
Professor Katsumi Maenaka, Hokkaido University, Japan
We are seeking a partner who could further develop and commercialize this technology. Sample for evaluation can be provided under MTA.